Literature DB >> 1328410

Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells.

W H Caselmann1, M Meyer, S Scholz, P H Hofschneider, R Koshy.   

Abstract

A hepatoblastoma cell line transfected with hepatitis B virus (HBV) DNA (Hep G2.2.15) was used to investigate the effects of interferons (IFNs) on HBV replication and hepatocellular gene expression. IFN-alpha 2b or -beta inhibited HBV replication transiently. In parallel, there was a decrease in the amount of HBV mRNA. Hepatitis B surface antigen and early antigen secretion were not influenced; however, their intracellular levels diminished during treatment. The cellular 2',5'-oligoadenylate synthetase activity was increased 9- to 18-fold during treatment of cells with IFN-gamma, -alpha, or -beta. The number of IFN-alpha and -beta receptors was down-regulated, while the number of IFN-gamma receptors remained constant. The expression of major histocompatibility complex class I antigens was stimulated by addition of IFN-alpha or -beta. These data show that both IFN-alpha and -beta can effectively inhibit HBV replication and induce a cellular IFN response in Hep G2.2.15 cells similar to that seen in humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328410     DOI: 10.1093/infdis/166.5.966

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

Authors:  Laura Belloni; Lena Allweiss; Francesca Guerrieri; Natalia Pediconi; Tassilo Volz; Teresa Pollicino; Joerg Petersen; Giovanni Raimondo; Maura Dandri; Massimo Levrero
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

Review 2.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  In vitro resistance to interferon of hepatitis B virus with precore mutation.

Authors:  Yan Wang; Lai Wei; Dong Jiang; Xu Cong; Ran Fei; Jiang Xiao; Yu Wang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

4.  Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus.

Authors:  Chunxiao Xu; Haitao Guo; Xiao-Ben Pan; Richeng Mao; Wenquan Yu; Xiaodong Xu; Lai Wei; Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein.

Authors:  E Gordien; O Rosmorduc; C Peltekian; F Garreau; C Bréchot; D Kremsdorf
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome.

Authors:  Flavio F Alcantara; Hong Tang; Alan McLachlan
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

7.  Inhibition of hepatitis B virus in tissue culture by alpha interferon.

Authors:  M G Davis; R W Jansen
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Fucoidan from Fucus vesiculosus suppresses hepatitis B virus replication by enhancing extracellular signal-regulated Kinase activation.

Authors:  Huifang Li; Junru Li; Yuan Tang; Lin Lin; Zhanglian Xie; Jia Zhou; Liyun Zhang; Xiaoyong Zhang; Xiaoshan Zhao; Zhengliang Chen; Daming Zuo
Journal:  Virol J       Date:  2017-09-16       Impact factor: 4.099

9.  Interferon Alpha Induces Cellular Autophagy and Modulates Hepatitis B Virus Replication.

Authors:  Jia Li; Thekla Kemper; Ruth Broering; Jieliang Chen; Zhenghong Yuan; Xueyu Wang; Mengji Lu
Journal:  Front Cell Infect Microbiol       Date:  2022-02-02       Impact factor: 5.293

Review 10.  Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.

Authors:  Madhan Jeyaraman; Sathish Muthu; Asawari Bapat; Rashmi Jain; E S Sushmitha; Arun Gulati; Talagavadi Channaiah Anudeep; Shirodkar Jaswandi Dilip; Niraj Kumar Jha; Dhruv Kumar; Kavindra Kumar Kesari; Shreesh Ojha; Sunny Dholpuria; Gaurav Gupta; Harish Dureja; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Saurabh Kumar Jha
Journal:  Heliyon       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.